SemBioSys Genetics of Canada Forms JV with Tasly Pharma

SemBioSys Genetics of Canada has formed a China JV with Tasly Pharma of Tianjin. In exchange for a 30% stake in the JV, SemBioGenetics will contribute its plant-made insulin and insulin analogues (excluding territories in which SemBioSys is pursuing other deals). The insulin products are in clinical development. SemBioSys positions the insulin, which is produced using safflower seeds, as a low-cost insulin biosimilar. More details.... Stock Symbols: (TSX: SBS) (SHA: 600535) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});